Addition of anti-CD25 to thymoglobulin for induction therapy: Delayed return of peripheral blood CD25-positive population

Junichiro Sageshima, Gaetano Ciancio, Jeffrey J. Gaynor, Linda Chen, Giselle Guerra, Warren Kupin, David Roth, Phillip Ruiz, George W. Burke

Research output: Contribution to journalArticle

18 Scopus citations


An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n=88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1mg/kg) (n=27) or thymoglobulin alone (4-7 doses; 1mg/kg) (n=23). SPK recipients received daclizumab (two doses; 1mg/kg) in addition to thymoglobulin (five doses; 1mg/kg). The return of peripheral blood CD25+ cells was delayed for 45d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.

Original languageEnglish (US)
JournalClinical Transplantation
Issue number2
StatePublished - Mar 1 2011
Externally publishedYes



  • IL-2 receptor
  • Kidney-pancreas transplant
  • T-cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Transplantation

Cite this